NCT03761849: A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
- State
- Completed
- Phase
- Phase 3
- People
- 899 taking part
- Started
- 23 Jan 2019
- Primary completion
- 24 Mar 2022
- Arms
- RO7234292 Q8W, RO7234292 Q16W
- Results
- Posted on the registry
- 3 Dec 2018: Trial registered
- 23 Jan 2019: Trial started
- 24 Mar 2022: Trial completed
- 7 Nov 2023: Trial results posted